|
|
News Breaks | | | | January 24, 2013 | | 09:16 EDT |  | CTIC | Cell Therapeutics has opportunity in MF, says Roth Capital
After attending Cell Therapeutics' Analyst Day, Roth Capital believes the company's pacritinib drug has a material opportunity to become a treatment for myelofibrosis, or MF, given the drug's differentiated profile of having a minimal effect on platelets. The firm maintains a $4 price target and Buy rating on the stock. | |
|
News For CTIC From The Last 14 Days Check below for free stories on CTIC the last two weeks. |
|
|
| May 20, 2013 | | 05:47 EDT |  | CTIC | Cell Therapeutics reports the G-BA issues final assessment report for Pixuvri
 Subscribe for More Information | |
|
|
|
|
|
|
